Nine days after we put a tobacco sleeve into seven model portfolios, the largest name in it poured concrete. Philip Morris International (PM) opened a $1.2 billion manufacturing campus in Aurora, Colorado, to expand production of Zyn nicotine pouches. The detail that matters is not the ribbon-cutting. It is the budget line.
A budget that doubled mid-build
The Aurora plant was announced in 2024 as a $600 million project. It opened as a $1.2 billion one. Construction took about 19 months, and the roughly 780,000-square-foot campus began commercial production earlier this month. It will serve as a production and export hub — for the U.S. first, then Asia, Latin America and the Caribbean.
“This facility expands our production capacity, strengthens our supply chain, and enhances our ability to serve growing demand,” said Stacey Kennedy, CEO of Philip Morris U.S. The company has invested about $1 billion so far and plans another $200 million over the next two years for the next phase. Last week it said it would ramp up U.S. investment to keep Zyn the go-to nicotine pouch for Americans.
Why a building is evidence
Companies say encouraging things about product transitions on every earnings call. Very few double a factory’s budget mid-construction for a product they privately doubt. Capital expenditure — capex, the money spent on plants and equipment — is the least ambiguous thing a management team discloses, because it cannot be revised in a footnote. A plant is a decade-long statement about expected volume.
That is why this page exists. On July 22 we bought the pouch transition rather than the cigarette: Philip Morris as the core position, British American Tobacco (BTI) where the mandate fits, and Altria (MO) in the income portfolios. Weights run roughly 1% to 6% across seven model portfolios, funded from cash and short bills. Nine days later, the largest holding in the sleeve spent $1.2 billion agreeing with us.
The underlying case has not changed since we wrote it. Jeremy Siegel found that Philip Morris was the single best-performing S&P 500 stock from 1957 to 2003, compounding at 19.75% a year against the index’s 10.85%. That is not an argument that tobacco is a nice business. It is an argument about what happens when a hated, cash-generating company reinvests dividends at a permanently cheap price. The full reasoning is in the July 22 sleeve note and the original July 10 trade note. Read them in that order.
The risk that did not move
A $1.2 billion building does not change a regulator’s mind. The category exists at the pleasure of the FDA, which can revisit flavors, nicotine levels or marketing at any point. If anything, a bigger domestic footprint makes the company a bigger target for the next rulemaking. That is why the sleeve is sized at 1% to 6% — never a concentrated bet.
Two housekeeping notes. The halal portfolio excludes tobacco permanently and is unaffected; individual client screens are honored automatically. And a footnote for the curious: Altria shows up later this week as the owner of one of America’s most generous retirement plans, contributing 13% to 17% in total. The house wins twice.